Lupin has launched Carbidopa tablets, used for the treatment of symptoms of Parkinson’s disease and parkinsonism, in the American market.
The company has launched the product in the strength of 25 mg after approval from the United States Food and Drug Administration (USFDA) earlier, Lupin said in a statement today.
The product is the generic version of Aton Pharma Inc’s Lodosyn tablets in the same strength, it added.
The tablets are indicated for use “with Carbidopa-Levodopa or with Levodopa for the treatment of symptoms of idiopathic Parkinson’s disease, postencephalitic parkinsonism, and symptomatic parkinsonism, which may follow injury to the nervous system by carbon monoxide intoxication and/or manganese intoxication,” Lupin said.
As per IQVIA MAT January 2018 data, Carbidopa tablets, 25 mg, had annual sales of approximately $17.4 million in the US market, Lupin said.
Shares of Lupin were trading up by 0.49 per cent at Rs 739.35 on the BSE.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.